CARB-X awards $24 million for new antibacterial products

via @CIDRAP at University of Minnesota

New antibiotic development is getting a much-needed shot in the arm.

CARB-X, a public-private initiative that aims to boost discovery and development of novel antibiotics and diagnostic tests to combat antibiotic resistance, announced today it will be awarding $24 million to 11 biotech companies working on new antibacterial products that target gram-negative bacteria.

The announcement marks the first phase of funding by CARB-X (the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a joint US and UK effort launched in July 2016 to help provide a financial boost for global antibacterial innovation and development, which has been hampered both by scientific challenges and a lack of financial incentives. CARB-X officials hope the funding will help accelerate research and bring new antibiotics to market faster.

“This is a great day for antibiotic research and development,” CARB-X executive director Kevin Outterson, JD, said at a press conference announcing the awards.

[Read more]

Back